European Growth
Opportunity
Over the last four years, Avextra has built one of the only vertically integrated EU operations from genetic selection and cultivation to sales and distribution. By effectively and responsibly deploying capital, we’ve built valuable assets strategically across Europe and are already present in some of the biggest EU markets.
Meet Avextra: Europe’s leader in Cannabis-based medicine
Assets strategically developed across Europe
Country access
via high calibre partners
Avextra license/
infrastructure
Cultivation
Production
Avextra controls the entire value chain
From genetic selection through to product innovation
Genetic Selection and Cultivation
Product Development and R&D
Production and Manufacturing
Distribution
Clinical Pipeline
GENETIC SELECTION aND CULTIVaTION
We have a 600m2 purpose-built cultivation facility on 250ha of land in Portugal to cultivate rare genetics for indication-based formulations.
Check out our state- of-the-art medical cannabis cultivation facility in Portugal in this behind-the-scenes.
1
PRODUCT DEVELOPMENT
aND R&D
Focused development of novel extract-based product innovations
2
PRODUCTION aND MaNUFaCTURING
In a 10,000m2 state-of-the-art GMP manufacturing facility in Germany and a highly qualified team with 75 years of experience in botanical extraction of plant-based medicines.
3
DISTRIBUTION
Our products are already present in 4 of the biggest EU markets with expansion plans in place. We have one of the largest sales team in Germany, equipped with exceptional connections.
Here you see some placeholder text to explain the picture.
4
CLINICaL PIPELINE
Clinical Program in place to gather product-specific data for future commercials, with 3 clinical programs starting in 2023.
We invest a third of our total budget in Research & Development
5
Press Releases
Avextra Portugal Unveils Advanced Breeding Program to Develop Proprietary THC and CBD Cultivars, Establishing a Key IP Pillar
Lisbon, Portugal, November 20, 2024 — Avextra Portugal is excited…
Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial
Bensheim, Germany, Oct. 08, 2024 — Avextra AG…
German start-up Avextra wants to develop “cannabis blockbusters”.
The Leading German Business Publication Handelsblatt did a profile on…
Avextra AG and SynQube GmbH announce a Strategic Partnership in Drug Development
Avextra and SynQube jointly announce their strategic partnership. Both partners…
Strategic
Partnerships
Goethe-Universität
Exclusive research partnership in oncology
DGS
Strategic research collaboration with the largest pain society in the EU.
INTEGRO MEDICAL CANNABIS CLINICS
50/50 owned UK based clinic with IPS Pharma.
Etain
Our formulation partner and shareholder. Leading New York licensed cannabis company.
BPI
Leveraging membership in pharmaceutical industry association
CESPU
Research collaboration on toxicology
We are always looking to connect with those who share our vision. If you’re interested in receiving a detailed deck and discovering how you can be part of our success, please contact us today.
CONTaCT US: